Journal of Pain and Symptom Management
Volume 28, Issue 2 , Pages 97-99 , August 2004

Psychostimulants: new concepts for palliative care from the modafinil experience?

References 

  1. Pace-Schott EF, Hobson JA. Basic mechanisms of sleep: new evidence on the neuroanatomy and neuromodulation of the NREM-REM cycle. In:  Davis KL,  Charney D,  Coyle JT,  Nemeroff C editor. Neuropsychophamacology. The fifth generation of progress. Philadelphia: Lippincott Williams & Wilkins; 2002;p. 1859–1877
  2. Silber MH, Rye DB. Solving the mystery of narcolepsy. The hypocretin story. Neurology. 2001;56:1616–1618
  3. Overeem S, Dalmau J, Bataller L, et al.  Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. Neurology. 2004;62:138–140
  4. Scammell TE, Estabrooke IV, McCarthy MT, et al.  Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci. 2000;20:8620–8628
  5. Ishizuka T, Sakamoto Y, Sakurai T, et al.  Modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett. 2003;339:143–146
  6. Ault A. Narcolepsy drug could be approved for wider use. Lancet. 2003;362:1128
  7. Kingshott RN, Vennelle M, Coleman EL, et al.  Randomized double blind placebo-controlled crossover trial of modafinil in the treatement of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med. 2001;163:918–923
  8. Pack A. Should a pharmaceutical be approved for the broad indication of excessive sleepiness?. Am J Respir Crit Care Med. 2003;167:109–111
  9. Vastag B. Poised to challenge need for sleep, “wakefulness enhancer” rouses concerns. JAMA. 2004;291(2):167–170
  10. Webster L, Andrews M, Stoddard G. Modafinil treatment of opiod-induced sedation. Pain Med. 2003;4:135–140
  11. Pappagallo M. Modafinil: a gift to portmanteau. Am J Hosp Palliat Care. 2001;18:408–410

PII: S0885-3924(04)00188-5

doi: 10.1016/j.jpainsymman.2004.04.006

Journal of Pain and Symptom Management
Volume 28, Issue 2 , Pages 97-99 , August 2004

Article Tools